SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (29619)12/14/1999 8:23:00 AM
From: Hippieslayer  Read Replies (2) | Respond to of 32384
 
targretin,panretin,and ontak...what is a ctcl patient to choose from? so many choices! the bad: three drugs for a very small population who have the disease. good: opp for off label uses..if that happens..

congrats...



To: Arthur Radley who wrote (29619)12/14/1999 8:35:00 AM
From: Henry Niman  Respond to of 32384
 
Today's online WSJ lists yesterday's Dow Jones report which quotes H&Q van den Broek on Targretin breast cancer application
207.235.5.146